CNSI Cambridge Neuroscience Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CNSI Cambridge Neuroscience

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (446)	12/22/1998 1:10:00 AM
From: molemania	Read Replies (1) of 675

Good post Mike - The potential royalty payments are not real big, but for a company the size of CNSI with a burn rate of only $300,000 a month now, they could mean a great deal. If they can keep the trials going for at least two or three years, the milestone payments will more than cover the burn rate, plus Bayer is paying for all related MS drug research and development costs (is this right or not?). This gives CNSI a good cushion, along with their existing $13 MM, and allows them time and resources to concentrate on the pain medication, Cerastat and the glaucoma drug. All in all it bodes well for the next couple of years and takes a lot of pressure off CNSI. Dave

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next